Arcus Biosciences (RCUS)
(Delayed Data from NYSE)
$18.09 USD
-0.28 (-1.52%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $18.09 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
RCUS 18.09 -0.28(-1.52%)
Will RCUS be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for RCUS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RCUS
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Tops Revenue Estimates
RCUS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Clearside Biomedical, Inc. (CLSD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Arcus Biosciences, Inc. (RCUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Is The Options Market Predicting a Spike In Arcus Biosciences (RCUS) Stock?
Other News for RCUS
Balanced Outlook: Hold Rating on Arcus Biosciences Amid Pipeline Challenges and Market Uncertainty
Commit To Buy Arcus Biosciences At $15, Earn 30.4% Annualized Using Options
Arcus Biosciences Inc (RCUS) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid ...
Microsoft, Qualcomm downgraded: Wall Street's top analyst calls
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday